AIBODY key facts
as of Oct 2026- Developer of a cloud-based digital physiology software designed to offer real-time, immersive medical simulations.
- AIBODY is valued at approximately $25.8M as of Oct 2026 (last reported valuation).
- It has raised $7.5M; the latest was Later Stage VC ($5.8M) in Mar 2025.
- Notable investors include Northstar Ventures, DigitalHealth.London Accelerator, Google Accelerator, Raw Ventures.
- Status: Privately Held (backing).
AIBODY's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·Watch AIBODY: the Monday email on marks, rounds and moves
AIBODY funding rounds
No funding rounds for AIBODY are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AIBODY valuation
AIBODY's last reported valuation was $25.8 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
AIBODY investors
4 investors are on record for AIBODY, including Northstar Ventures, DigitalHealth.London Accelerator, Google Accelerator and Raw Ventures.
About AIBODY
Developer of a cloud-based digital physiology software designed to offer real-time, immersive medical simulations. The company's software provides detailed physiological responses to virtually any simulated medical condition or treatment protocol, enabling medical professionals to speed up human physiology teaching using the digital human body and other technology systems.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 25
- Website
- aibody.io/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.